BrainsWay Ltd. (BWAY) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$16.41
Price Target
$15.00
Target Range
$15.00 — $15.00
Analyst Rating
Buy
Forward P/E84.2x
Trailing P/E45.6x
Forward PEG—
Implied Growth-46.6%
Median Target$15.00
Analyst Spread0.0%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$15
-8.6%
Consensus
$15
-8.6%
Bull Case
$15
-8.6%
BWAY Price Target Analysis
Updated May 7, 2026As of May 7, 2026, BrainsWay Ltd. (BWAY) has a Wall Street consensus price target of $15.00, based on estimates from 6 covering analysts. With the stock currently trading at $16.41, this represents a potential downside of -8.6%. The company has a market capitalization of $322M.
Analyst price targets range from a low of $15.00 to a high of $15.00, representing a 0% spread in expectations. The median target of $15.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 5 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, BWAY trades at a trailing P/E of 45.6x and forward P/E of 84.2x. Analysts expect EPS to grow -46.6% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+71.6%
Avg Forward P/E16.4x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 STIMNeuronetics, Inc. | $133M | $1.91 | $8.00 | +318.8% | Buy | — | 7 |
 NVCRNovoCure Limited | $1.9B | $16.50 | $33.50 | +103.1% | Buy | — | 15 |
 LIVNLivaNova PLC | $3.6B | $66.26 | $75.88 | +14.5% | Buy | 15.7x | 14 |
 GKOSGlaukos Corporation | $7.9B | $135.27 | $146.67 | +8.4% | Buy | — | 24 |
 ELMDElectromed, Inc. | $215M | $25.94 | $38.00 | +46.5% | Buy | 23.6x | 4 |
 ABTAbbott Laboratories | $150.0B | $86.25 | $128.71 | +49.2% | Buy | 15.7x | 41 |
 MDTMedtronic plc | $99.5B | $77.60 | $109.50 | +41.1% | Buy | 14.1x | 49 |
 BSXBoston Scientific Corporation | $83.2B | $56.00 | $91.33 | +63.1% | Buy | 16.6x | 43 |
 HOLXHologic, Inc. | $17.0B | $76.01 | $79.00 | +3.9% | Hold | 17.2x | 42 |
 INVAInnoviva, Inc. | $1.9B | $22.52 | $37.67 | +67.3% | Buy | 11.8x | 10 |
Upside Potential Comparison
STIMNVCRINVABSXABTELMDMDTLIVNSee BWAY's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BWAY Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BWAY vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBWAY — Frequently Asked Questions
Quick answers to the most common questions about buying BWAY stock.
What is the BWAY stock price target for 2026?
Wall Street's consensus price target for BWAY is $15, -8.6% from its current price of $16.41. The below-market target from 6 analysts suggests limited near-term appreciation.
Is BWAY a buy, sell, or hold?
BWAY has a consensus rating of "Buy" based on 6 Wall Street analysts. The rating breakdown is predominantly bullish, with 5 Buy/Strong Buy ratings. The consensus 12-month price target of $15 implies -8.6% downside from current levels.
Is BWAY stock overvalued or undervalued?
At a forward P/E of 84.1538x, BWAY trades at a premium valuation. The consensus price target of $15 (-8.6% downside) suggests analysts may view current valuations as stretched.
How high can BWAY stock go?
The most bullish Wall Street analyst has a price target of $15 for BWAY, while the most conservative target is $15. The consensus of $15 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover BWAY stock?
BWAY is moderately covered, with 6 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 5 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the BWAY stock forecast?
The 12-month BWAY stock forecast based on 6 Wall Street analysts shows a consensus price target of $15, with estimates ranging from $15 (bear case) to $15 (bull case). The median consensus rating is "Buy".
What is BWAY's forward P/E ratio?
BWAY trades at a forward P/E ratio of 84.2x based on next-twelve-months earnings estimates compared to a trailing P/E of 45.6x. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy BWAY stock?
Analysts are cautious on BWAY, with 0 Sell ratings and a price target of $15 (-8.6% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do BWAY price targets vary so much?
BWAY analyst price targets range from $15 to $15, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $15 consensus represents the middle ground.